Archive | April, 2013

Frothy Biotechs Hit By Amgen Earnings- Reiterate Caution

Biotech Sector Off All Time Highs This Week-IBB Down 2.5% The biotech melt-up that coincided with the surprising Vertex (VRTX) 60% move on April 19 has run its course and the IBB is now 7 pts off the all time high of $177.  Vertex was off 4.75% today. Daily trading volume was double the average. […]

Continue Reading 0

Rayno Life Science and Tools: Performance Summary April 21 YTD

A Great Quarter for Many Tools and Diagnostic Stocks The tools and diagnostics sector usually underperforms biopharmaceuticals because the companies are more tethered to deal news and fundamentals. We will review our focus stocks below as Q1 earnings come in. NASDAQ is down about 3% over the last 5 trading days so many of the […]

Continue Reading 0

BIO Meeting in Chicago Next Week

I am at BIO next week and will probably not be posting for several days: 2013 BIO International Convention   Here are some of the key sessions: Schedule at a Glance | 2013 BIO International Convention  

Continue Reading 0

Rayno Life Sciences-Biopharmaceutical Update: Turbo Boost From Vertex (VRTX)

Vertex Pharmaceuticals Gives Biotech Sector A Turbo Boost Vertex (VRTX $82), a laggard in the frothy biotech universe rose an astonishing 58% on positive Phase 2 clinical news from its cystic fibrosis drug VX-661. The study showed statistically significant improvement in lung function among adults who have two copies (homozygous) of the most common mutation […]

Continue Reading 0

Risk Off Resumes After One Day Rally: Caution on QQQ,IBB

Major Sell-Off Early On April 17–Correction is Here with Some Technical Damage Posted 12.15p EDT, Update at 4:56p The rally yesterday was apparently a head fake as a major sell-off resumed today with the NASDAQ down 2.10% and the S&P down 1.7%. The gold free fall on Monday foreshadowed liquidation of equities as investors have […]

Continue Reading 0

Gold Liquidation Is Infecting Equities- Even Biotech With NASDAQ Down 1.6%

Gold Crash Spooks Traders-Life Science Stocks Lose Resilience IBB ($166.82) Down 1.6% Rayno Life Science Stocks- Quick Look With NAZ at 2343 We have not made any Rayno Portfolio changes but have added two stocks recently: Genomic Health (GHDX) and Hologic (HOLX) both down about 1.3% today. The big news today is ThermoFisher (TMO $80.23) […]

Continue Reading 0

Risk Off Day-Retail Sales Disappoint But Life Science and Drug Stocks Hold

Biotech and Drug Stocks Remain in the Sweet Spot NAZ Down 0.16% at 3295 at Close A string of market up days was halted today as retail sales and consumer sentiment gave bearish indicators.Commodity stocks were also weak-energy down 1.2%, materials down 1.7%– and there is a “whiff of deflation” in the air according to […]

Continue Reading 0

Rayno Life Science Winners: EXAS, HOLX,TMO

Life Science Stocks Blow Through New Highs The Rayno Biopharma stocks continued their run today and some Tools/DX stocks are freshening up. Yesterday we added Hologic (HOLX) as a turnaround/value play and it is up 1.73%. Other Rayno winners in this lagging sector today are : Alere (ALR), Cepheid (CPHD), Exact Sciences (EXAS), Genomic Health (GHDX), […]

Continue Reading 0

They Are Buying Everything Today: Biotechs, Financials,and Especially Techs (XLK)

Concern About FED Tightening Reverses Psychology And Becomes Another Reason To Buy Equities QE May End This Summer FED minutes were released early showing concern about exit from $4T inventory of bonds and further effects of QE like the current asset bubble, future inflation or losses from balance sheet.But economic conditions may still warrant further […]

Continue Reading 0

Rayno DX and Tools: Hologic (HOLX) added

Hologic (HOLX) Offers Good Long Term Value We will add Hologic Inc. to our Diagnostics and Tools Portfolio. Prior to its acquisition by Hologic we had GenProbe Inc. on our focus list. Hologic (HOLX $21.70), Market Cap of $5.84B, offers good long term value with a Price/Sales of 2.7, book value of $2.984B, P/B of  1.94 […]

Continue Reading 0